Moreover, elevated plasma NLRP3 and SASP-related inflammatory mediators are associated with an increased risk of cardiovascular events, cardiovascular mortality, and all-cause mortality in patients with CKD, observations supported by the CANTOS (interleukin-1ß) [59] and RESCUE (interleukin-6) [60] trials. Here, NLRP3 is linked to chronic kidney disease.